INVA
Innoviva, Inc. Common Stock
stockNASDAQ
innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 19.10 | 2026-11-06 | -0.37% | -0.485 |
| 1M | 20.74 | 2026-10-13 | -8.24% | 1.069 |
| 3M | 20.75 | 2026-08-13 | -8.29% | 0.841 |
| 6M | 23.14 | 2026-05-13 | -17.76% | 0.200 |
| 1Y | 22.20 | 2025-11-13 | -14.28% | 0.309 |
| 2Y | 20.10 | 2024-11-13 | -5.32% | — |
| 5Y | 17.76 | 2021-11-12 | +7.15% | 0.122 |
Innoviva, Inc. Common Stock (NASDAQ:INVA) stock price today is $19.03, and today's volume is 560,907. INVA is up 0.316% today. The 30 day average volume is 803,867. INVA market cap is $1.35B with 71.08M shares outstanding.